Pharmaxis Ltd operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Pharmaxis Ltd with three other
companies in this sector in AUSTRALIA :
sales of 13.94 million Australian Dollars [US$10.76 million]
of which 99%
was Cancer Immunotherapy),
Idt Australia Limited.
(14.17 million Australian Dollars [US$10.94 million]
(7.48 million Australian Dollars [US$5.78 million]
of which 79%
was Advangen Japan).
During the year ended June of 2020, sales at
Pharmaxis Ltd were A$12.55 million (US$9.69 million).
a very small
increase of 0.0%
versus 2019, when the company's sales were A$12.55 million.
Despite this increase, sales are still
below the level achieved in 2018, when Pharmaxis Ltd
reported sales of A$50.33 million.
Sales of Mannitol saw an increase
that was more than double the company's growth rate: sales were up
23.6% in 2020, from
A$5.70 million to A$7.05 million.
Not all segments of Pharmaxis Ltd experienced an increase in sales in 2020:
sales of New Drug Development fell 13.5% to A$5.16 million.
Pharmaxis Ltd also experienced decreases in sales in
Corporate (down 9.3% to A$459,000.00 )